Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
12/24/13Medgenics Announces Director Enters into Stock Trading Plan and Change of Adviser
MISGAV, Israel & WAYNE, Pa.--(BUSINESS WIRE)--Dec. 24, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of BiopumpTM, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that, on 23 December 2013, Dr. Andrew L. Pearlman, founder and a director, has established a personal stock trading plan in accordance both with the guidelines ... 
Printer Friendly Version
12/18/13Medgenics Reports Open Market Purchase of Common Stock by Director
WAYNE, Pa & MISGAV, Israel--(BUSINESS WIRE)--Dec. 18, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that the Company was informed today by Dr. Alastair Clemow, a director of the Company that he purchased 4,500 shares of common stock on the open market on December ... 
Printer Friendly Version
12/16/13Medgenics Reports Open Market Purchase of Common Stock by Chairman of the Board
WAYNE, Pa. & MISGAV, Israel--(BUSINESS WIRE)--Dec. 16, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that on December 13, 2013, the Company was informed by Dr. Sol Barer, Medgenics’ Chairman of the Board of Directors, that he purchased 20,000 shares of common stock... 
Printer Friendly Version
12/04/13Medgenics to Present at the Oppenheimer 24th Annual Healthcare Conference
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Dec. 4, 2013-- Medgenics, Inc. (NYSE MKT:MDGN and AIM:MEDU, MEDG) (the Company), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that Company management will participate in the Oppenheimer 24th Annual Healthcare Conference taking place from December 10-11, 2013 in New York City. Michael Co... 
Printer Friendly Version
12/04/13Medgenics Reports Sale of Common Stock by Director
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Dec. 4, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of BiopumpTM, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that on December 2, 2013 and December 3, 2013, the Company was informed by Dr. Eugene Bauer, a Director of the Company, that he sold a total of 20,000 shares of co... 
Printer Friendly Version
12/03/13Medgenics Reports Open Market Purchase of Common Stock by Chairman of the Board
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Dec. 3, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that on December 2, 2013, was informed by Dr. Sol Barer, Medgenics’ Chairman of the Board of Directors, that he purchased 20,000 shares of common stock on the ope... 
Printer Friendly Version
11/07/13Medgenics Reports Third Quarter Financial Results
Business Update Conference Call Scheduled for Tomorrow at 8:30 a.m. Eastern time MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Nov. 7, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported financial results for the three and nine months ended September 30, 2013 and ... 
Printer Friendly Version
11/04/13Medgenics to Host Business Update Conference Call on Friday, November 8th at 8:30 a.m. Eastern time
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Nov. 4, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that the Company will host an investment community conference call on Friday, November 8, 2013 beginning at 8:30 a.m. Eastern time to provide a business update and to answer ... 
Printer Friendly Version
10/27/13Medgenics Reports Positive Data with Second-Generation Viral Vectors at European Society of Gene and Cell Therapy Congress
Second-generation gene therapy vectors demonstrate improved levels and durability of therapeutic protein secretion in vitro and in vivo Plans to initiate confirmatory human trials in the first half of 2014 MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Oct. 27, 2013-- Medgenics, Inc. (NYSE MKT:MDGN and AIM:MEDU, MEDG), developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using the... 
Printer Friendly Version
10/23/13Medgenics to Present Poster at European Society of Gene and Cell Therapy Congress to Highlight Results from Second-Generation Viral Vector
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Oct. 23, 2013-- Medgenics, Inc. (NYSEMKT:MDGN)(AIM:MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that a poster highlighting the Company’s second-generation EPODURE Biopump™ will be presented at the European Society of Gene and Cell Therapy Congress, taking place in Madrid O... 
Printer Friendly Version
10/17/13Medgenics Appoints Biopharmaceutical Industry Veteran Bill Gantz to its Board of Directors
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Oct. 17, 2013-- Medgenics, Inc. (NYSE MKT:MDGN and AIM:MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces the appointment of Wilbur H. (Bill) Gantz to the Company’s Board of Directors effective October 16, 2013. With this appointment, the size of the Medgenics board increases to... 
Printer Friendly Version
09/16/13Medgenics Announces New Executive Leadership Team
New team includes President and CEO Michael Cola formerly with Shire and Safeguard Scientifics, CFO John Leaman formerly with Shire and McKinsey, and Global Head of R&D Garry Neil formerly with Apple Tree Partners and Johnson & Johnson MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Sep. 16, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), developer of a novel technology for the sustained production and delivery of the... 
Printer Friendly Version
08/06/13Medgenics Reports Second Quarter Financial Results
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Aug. 6, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported financial results for the three and six months ended June 30, 2013 and the filing with the U.S. Securities and Exchange Commission (SEC) of the Company’s Quarterly Rep... 
Printer Friendly Version
07/09/13Medgenics Awarded $1.9 Million Grant from the Israeli Office of the Chief Scientist
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Jul. 9, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported that its wholly owned subsidiary, Medgenics Medical Israel Ltd. (MMI), was awarded a government grant of up to NIS 6.7 million (approximately USD 1.9 million), from th... 
Printer Friendly Version
07/08/13Medgenics to Present at the 8th Annual JMP Securities Healthcare Conference
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Jul. 8, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics, will be presenting a corporate overview at the 8th Annual JMP Securities Healthcar... 
Printer Friendly Version
05/09/13Medgenics Reports First Quarter 2013 Financial Results
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--May. 9, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported financial results for the three months ended March 31, 2013 and the filing with the U.S. Securities and Exchange Commission (“SEC”) of the Company’s Quarterly Report o... 
Printer Friendly Version
05/01/13Medgenics Announces Results of 2013 Annual Meeting of Stockholders
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--May. 1, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company” or “Medgenics”),, the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announces that all resolutions proposed at the Company’s Annual Meeting of Stockholders held yesterday were duly passed. Each of the current dire... 
Printer Friendly Version
04/25/13Medgenics Reports Positive Interim Results from Ongoing Phase IIa Study of EPODURE to Treat Anemia in Dialysis Patients
Data will be used to support Phase II trial in U.S. MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Apr. 25, 2013-- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of Biopump™, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today provided an update on results from the first four patients treated thus far in its ongoing Phase IIa clinica... 
Printer Friendly Version
04/22/13Medgenics Receives Notice of Allowance from the U.S. Patent Office for Claims That Expand IP for Its Platform Technology to Additional Therapeutic Proteins
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Apr. 22, 2013-- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of Biopump™, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced the United States Patent and Trademark Office has issued a Notice of Allowance of claims that expand the Company’s scope of patent coverage for additional... 
Printer Friendly Version
04/18/13Medgenics to Present at the 12th Annual Needham Healthcare Conference
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Apr. 18, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company” or “Medgenics”), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics, will be presenting a corporate overview at the 12th Annua... 
Printer Friendly Version
03/26/13Medgenics Announces Exercise by Underwriters of Over-Allotment Option
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Mar. 26, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company” or “Medgenics”), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that, in connection with its previously announced public offering, the underwriters have exercised their option to purchase 470,000 shares of... 
Printer Friendly Version
03/15/13Medgenics to Present at the 25th Annual Roth Conference
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Mar. 15, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company” or “Medgenics”), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics, will deliver a corporate overview at the 25th Annual ... 
Printer Friendly Version
03/14/13Medgenics Reports 2012 Financial Results
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Mar. 14, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company” or “Medgenics”), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced financial results for the fiscal year ended December 31, 2012 and the filing with the U.S. Securities and Exchange Commission (“SEC”) of ... 
Printer Friendly Version
03/12/13Medgenics Appoints Former Chairman and CEO of UBS Financial Services Joseph J. Grano, Jr. to Board of Directors
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Mar. 12, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company” or “Medgenics”), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces the appointment of Joseph J. Grano, Jr. to the Company’s Board of Directors effective March 15, 2013. Mr. Grano’s appointment fills the vacancy... 
Printer Friendly Version
02/14/13Medgenics Announces Closing of Public Offering of Common Stock and Warrants
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Feb. 14, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company” or “Medgenics”), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces yesterday’s closing of an underwritten public offering of 5,600,000 shares of common stock and Series 2013-A warrants to purchase up to an aggr... 
Printer Friendly Version
02/08/13Medgenics Prices Public Offering of Common Stock and Warrants
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Feb. 8, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company” or “Medgenics”), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has priced an underwritten public offering of 5,600,000 shares of common stock and Series 2013-A warrants to purchase up to an agg... 
Printer Friendly Version
01/30/13Medgenics Launches First Clinical Trial in Hepatitis to Use INFRADURE Tissue Treatment
Phase I/II Study in Hepatitis C Expected to Provide Gateway to Hepatitis B and D MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Jan. 30, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announced today that the first patient has been enrolled in a Phase I/II... 
Printer Friendly Version
01/04/13Medgenics, Inc. (the “Company”) Issue of Options and Restricted Shares to Directors and Officers
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Jan. 4, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that, on 2 January 2013 it (i) granted options to subscribe for 15,000 shares of the Company’s common stock, par value US$0.0001 (“Common Shares”) (“Options”) and (ii) made a restricte... 
Printer Friendly Version